These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 26517190)

  • 1. Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection.
    Sluis-Cremer N; Wainberg MA; Schinazi RF
    Future Microbiol; 2015; 10(11):1773-82. PubMed ID: 26517190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
    Ghosn J; Chaix ML; Delaugerre C
    AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Balzarini J
    Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).
    de Béthune MP
    Antiviral Res; 2010 Jan; 85(1):75-90. PubMed ID: 19781578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Parrotta L; Perno CF; Svicher V
    Drug Resist Updat; 2011 Jun; 14(3):141-9. PubMed ID: 21295512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.
    Toni TD; Masquelier B; Lazaro E; Dore-Mbami M; Ba-Gomis FO; Téa-Diop Y; Kouakou K; Diby J; Sia E; Soppi S; Essien S; Schrive MH; Pinson P; Chenal H; Fleury HJ
    AIDS Res Hum Retroviruses; 2005 Dec; 21(12):1031-4. PubMed ID: 16379606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.
    Jackson JB; Becker-Pergola G; Guay LA; Musoke P; Mracna M; Fowler MG; Mofenson LM; Mirochnick M; Mmiro F; Eshleman SH
    AIDS; 2000 Jul; 14(11):F111-5. PubMed ID: 10983633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Etravirine: genetic barrier and resistance development].
    Llibre JM; Santos JR; Clotet B
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():32-9. PubMed ID: 20116626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nevirapine resistance after single dose prophylaxis.
    Eshleman SH; Jackson JB
    AIDS Rev; 2002; 4(2):59-63. PubMed ID: 12152519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impacts of HIV-1 resistance mutations associated with nucleoside reverse transcriptase inhibitors on viral fitness].
    Zhou Q; Liao LJ; Huang HJ
    Bing Du Xue Bao; 2012 May; 28(3):291-6. PubMed ID: 22764534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
    Kurle SN; Gangakhedkar RR; Sen S; Hayatnagarkar SS; Tripathy SP; Paranjape RS
    AIDS Res Hum Retroviruses; 2007 May; 23(5):682-5. PubMed ID: 17530993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1.
    Das K; Arnold E
    Curr Opin Virol; 2013 Apr; 3(2):111-8. PubMed ID: 23602471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CRF01_AE-specific polymorphic mutations G335D and A371V in the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors.
    Tanuma J; Hachiya A; Ishigaki K; Gatanaga H; Lien TT; Hien ND; Kinh NV; Kaku M; Oka S
    Microbes Infect; 2010 Dec; 12(14-15):1170-7. PubMed ID: 20713171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
    Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
    Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
    Menéndez-Arias L; Betancor G; Matamoros T
    Antiviral Res; 2011 Nov; 92(2):139-49. PubMed ID: 21896288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.